Thomas Weiser
Boehringer Ingelheim Pharma KG
Department of CNS Research
Ingelheim
Germany
[email]@ing.boehringer-ingelheim.com
Name/email consistency: high
- AMPA receptor antagonists with additional mechanisms of action: new opportunities for neuroprotective drugs?. Weiser, T. Curr. Pharm. Des. (2002)
- Inhibition of tetrodotoxin (TTX)-resistant and TTX-sensitive neuronal Na(+) channels by the secretolytic ambroxol. Weiser, T., Wilson, N. Mol. Pharmacol. (2002)
- Characterization of the anticonvulsant and neuroprotectant BIIR 561 CL in vitro: effects on native and recombinant alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. Weiser, T., Iizuka, M., Nishimura, S., Akiba, I., Barsoumian, E., Zhou, M., Steinhäuser, C., Brenner, M., Palluk, R., Wienrich, M. Naunyn Schmiedebergs Arch. Pharmacol. (2000)
- BIIR 561 CL: a novel combined antagonist of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors and voltage-dependent sodium channels with anticonvulsive and neuroprotective properties. Weiser, T., Brenner, M., Palluk, R., Bechtel, W.D., Ceci, A., Brambilla, A., Ensinger, H.A., Sagrada, A., Wienrich, M. J. Pharmacol. Exp. Ther. (1999)